Spikevax COVID-19 vaccine: what US patients should know

Spikevax is Moderna's mRNA COVID-19 vaccine, used across the US to help prevent severe illness from current variants. Here is how it works, who can get it, and what to ask your doctor.

Spikevax is Moderna's mRNA COVID-19 vaccine used to help prevent COVID-19 in adults and children in the United States, under guidance from the US Food and Drug Administration (FDA) as updated in 2024 FDA, 03/14/2024.

As of: 05/24/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Spikevax
• Category: mRNA COVID-19 vaccine
• Brand/Manufacturer: Moderna
• Primary Use Cases: Prevention of symptomatic and severe COVID-19
• Availability: Widely available in the US through healthcare providers and pharmacies
• Core Markets: North America, Europe, and other regions with COVID-19 vaccination programs

What Spikevax Is and How It Works

Spikevax is an mRNA vaccine that teaches the body's cells to make a piece of the SARS-CoV-2 spike protein so the immune system can recognize and respond to the virus if exposed later Moderna, 02/22/2024.

The mRNA in Spikevax is enclosed in tiny lipid nanoparticles. After injection into the upper arm muscle, cells take up the mRNA, briefly produce the spike protein fragment, and trigger immune responses. The mRNA does not enter the cell nucleus and is broken down within days CDC, 01/15/2024.

Spikevax does not contain live virus and cannot cause COVID-19. Instead, it prepares the immune system to respond more quickly and strongly if a person is exposed to the virus in the future, reducing the risk of moderate and severe disease NFID, 12/12/2024.

Why Spikevax Matters for US Consumers and Industry

In the US, Spikevax is part of the national COVID-19 vaccination strategy, alongside other vaccines. The Centers for Disease Control and Prevention (CDC) recommends updated COVID-19 vaccines to help protect against currently circulating variants each season CDC, 03/01/2025.

For many Americans, updated Spikevax doses are offered in doctors' offices, pharmacies, community health centers, and workplace clinics. Vaccination can help reduce missed workdays, lower the risk of hospital strain, and support more stable operation of schools and businesses across the country NFID, 12/12/2024.

People with certain medical conditions, older adults, and some frontline workers have higher risks from COVID-19. For these groups, clinicians often view mRNA vaccines like Spikevax as an important tool to reduce severe outcomes when combined with other measures such as ventilation and testing CDC, 09/18/2024.

Spikevax in the US and Global Market

Moderna's Spikevax has been authorized or approved in multiple regions, including the United States, the European Union, and Canada, with composition updates that target currently circulating variants as recommended by regulators EMA, 10/24/2024.

Within the US, Spikevax competes with other COVID-19 vaccines that use mRNA or protein-based technologies. The market continues to evolve as public health agencies refine guidance on booster timing and eligible groups based on variant trends and surveillance data FDA, 11/08/2024.

Outside the US, countries incorporate Spikevax into national immunization programs depending on local supply, logistics, and regulatory decisions. This global use supports ongoing demand for updated formulations aligned with variant monitoring by international health authorities.

• mRNA vaccine using SARS-CoV-2 spike protein instructions
• Given as an injection in the upper arm muscle
• Used for prevention of COVID-19 in eligible age groups
• Updated compositions follow variant recommendations from regulators
• Available across the US in clinics and pharmacies

Frequently Asked Questions About Spikevax

How is Spikevax different from traditional vaccines?
Spikevax uses mRNA technology, which delivers instructions for cells to make a harmless spike protein fragment instead of using weakened or inactivated virus. The immune system then builds responses against that protein.

Who can receive Spikevax in the United States?
Eligibility depends on age, health status, and current CDC and FDA guidance. Updated recommendations specify which age groups and risk categories should receive seasonal doses. Patients should check current guidance with their healthcare provider.

Can Spikevax cause COVID-19?
No. Spikevax does not contain live coronavirus and cannot cause COVID-19 infection. It teaches the immune system to recognize the spike protein so it can respond more effectively if exposed to the actual virus later.

Spikevax is developed and marketed by Moderna, a biotechnology company based in Cambridge, Massachusetts, that focuses on mRNA-based medicines across infectious diseases and other therapeutic areas.

Moderna's shares are listed on the Nasdaq Global Select Market in the United States, and the company is associated with the ISIN US60770K1079 as part of its capital markets presence.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.